Computational approach to understanding the mechanism of action of isoniazid, an anti-TB drug  by Jena, Lingaraja et al.
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 3 ( 2 0 1 4 ) 2 7 6 –2 8 2
.sc iencedi rect .comHO ST E D  BY Avai lab le at wwwScienceDirect
journal homepage: www.elsev ier .com/ locate / IJMYCOComputational approach to understanding
the mechanism of action of isoniazid, an anti-TB
drughttp://dx.doi.org/10.1016/j.ijmyco.2014.08.003
2212-5531/ 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights reserved.
* Corresponding author. Address: JB Tropical Disease Research Centre, Mahatma Gandhi Institute of Medical Sciences, Sev
102, Wardha, Maharashtra, India. Tel.: +91 7152 284341/284355x262, 303; fax: +91 (07152) 284038.
E-mail addresses: bc_harinath@yahoo.com, info@jbtdrc.org (B.C. Harinath).Lingaraja Jena a, Pranita Waghmare a, Supriya Kashikar b, Satish Kumar a,
Bhaskar C. Harinath a,*
a Bioinformatics Centre, Biochemistry & JBTDRC, MGIMS, Sevagram, Maharashtra, India
b GeNext Genomics Pvt. Ltd., Nagpur, Maharashtra, IndiaA R T I C L E I N F O
Article history:
Received 2 August 2014
Accepted 5 August 2014
Available online 2 September 2014
Keywords:
Isoniazid
KatG
InhA
Drug resistance
MutationA B S T R A C T
Tuberculosis (TB) is an ancient disease caused by Mycobacterium tuberculosis (MTB), which
remains a major cause for morbidity and mortality in several developing countries. Most
drug-resistant MTB clinical strains are resistant to isoniazid (INH), a first-line anti-TB drug.
Mutation in KatG, a catalase-peroxidase, of MTB is reported to be a major cause of INH
resistance. Normally upon activation by KatG, INH is converted to an active intermediate
which has antimycobacterial action in MTB. This INH intermediate in the presence of
NADH forms INH-NAD adduct which inhibits inhA (2-trans-enoyl-acyl carrier protein
reductase) of MTB, thus blocking the synthesis of mycolic acid, a major lipid of the myco-
bacterial cell wall. In this docking study, the high binding affinity of INH-NAD adduct
towards InhA was observed in comparison with INH alone. In this study, two resistant
mutants of KatG (S315Tand S315N) were modeled using Modeller9v10 and docking analysis
with INH was performed using AutoDock4.2 and the docking results of these mutants were
compared with the wild type KatG. Docking results revealed the formation of a single
hydrogen (H) bond between the secondary amine nitrogen (–NH) of INH with Thr or Asn
residues in place of Serine at 315 position of KatG mutant strains respectively, whereas
in the case of the wild type, there was no H-bond formation observed between INH and
Ser315. The H-bond formation may prevent free radical formation by KatG in mutant
strains thus the development of resistance to the drug. This in silico evidence may implicate
the basis of INH resistance in KatG mutant strains.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
Decades after the discovery of the Mycobacterium tuberculosis
(MTB) organism, tuberculosis (TB) remains a major cause ofmorbidity and mortality in several developing countries.
Nearly 33% of the world’s population is considered to be
infected with MTB infection, with 8.6 million new patients
and 1.3 million deaths in the year 2012, including 320,000agram 442
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were 2.0 million to 2.4 million infected cases of TB, i.e., 26%
of total cases [1]. Multi-drug-resistant strains of this pathogen,
emerging in association with HIV, have added a frightening
dimension to the problem [2]. Outbreaks of extensively drug-
resistant (XDR) tuberculosis have also been an increasing
threat in certain regions around the world [3]. Most drug-
resistant MTB clinical strains are resistant to isoniazid (INH,Fig. 1 – Chemical structure of Isoniazid (Form
Table 1 – Proteins of Mycobacterium tuberculosis reported to asso
Locus_tag Name Prot
Rv1772 Hypothetical protein Rv1772 103
Rv1909c Ferric uptake regulation protein furA (fur) 150
Rv0340 Hypothetical protein Rv0340 179
Rv2428 Alkyl hydroperoxide reductase subunit C 195
Rv1483 3-Oxoacyl-[acyl-carrier-protein] reductase 247
Rv1484 Enoyl-(acyl carrier protein) reductase 269
Rv3566c Arylamine n-acetyltransferase nat 283
Rv2243 Acyl-carrier-protein S-malonyltransferase 302
Rv0129c Secreted antigen 85-C FBPC (85C)
(antigen 85 complex C) (AG58C)
(fibronectin-binding protein C)
340
Rv2242 Hypothetical protein Rv2242 414
Rv2245 3-Oxoacyl-(acyl carrier protein) synthase II 416
Rv1592c Hypothetical protein Rv1592c 446
Rv1854c NADH dehydrogenase 463
Rv3139 Acyl-CoA dehydrogenase FADE24 468
Rv2247 Acetyl/propionyl-CoA carboxylase beta
subunit AccD6
473
Rv0341 Isoniazid inducible gene protein INIB 479
Rv0343 Isoniazid inducible gene protein INIC 493
Rv2846c Integral membrane efflux protein EfpA 530
Rv0342 Isoniazid inducible gene protein INIA 640
Rv1908c Catalase–peroxidase-peroxynitritase T KatG 740
Rv3795 Integral membrane indolylacetylinositol
arabinosyltransferase EMBB
1098
Rv2427a Transcriptional regulator OxyR0, pseudogeneisonicotinic acid hydrazine) – a first-line, anti-tuberculous
drug [4].
Isoniazid (INH), also known as isonicotinyl hydrazine, is an
organic compound used as a first-line drug in the prevention
and treatment of TB. It has a simple structure (Fig. 1) contain-
ing two essential components required for the high activity
against MTB, i.e., a pyridine ring and a hydrazide group [5].
This compound was first synthesized in the early 20thula: C6H7N3O; Mol. Wt.: 137.139 g/mol).
ciate with Isoniazid resistance.
ein length Locus PDB ID Mutation
– – Thr4Ala
furA – Ser5Pro
– – Val163Ile
ahpC 2BMX Inter-genic region G(46)A
fabG1 1UZL Ala5Pro, Val14Leu, Thr21Ala
inhA 1P44 Lys8Asn, Ile16Thr, Ile21Val/
Thr, Ile47Thr, Val78Ala,
Ser94Ala/Leu, Ile95Pro,
Ile95Thr, Ile194Thr,
Arg202Gly, Glu217Asp,
promoter region
nat 4BGF Gly67Arg, Gly207Glu
fabD 2QC3 Ser275Asn
fbpC 4MQM Gly158Ser 63(C/T), 23(A/C)
– – Asp3Gly, Met323Thr
kasA 4C6U Asp66Asn, Met77Ile,
Arg121Lys,
Gly269Ser,Gly312Ser,
Gly387Asp, Phe413Leu
– – Pro42Leu, Val430Ala
ndh – Arg13Cys, Val18Ala,
Thr110Ala, Leu239Pro,
Arg268His
fadE24 – Insertion of 2 base pair (bp)
at nucleotide position -64
accD6 4FB8 Asp229Gly
iniB – Deletion of 12 bp at
nucleotide position 665
iniC – Trp83Gly
efpA – Ile73Thr
iniA – Pro3Ala, Arg537His
katG 2CCA Ser315Thr, Ser315Asn,
Arg463Leu, Ser17Asn,
Gly19Asp, Ser140Asn/Arg,
Gly279Asp, Gly285Asp,
Gly316Asp, Ser457Ile,
Gly593Asp
embB – Tyr333His
oxyR0 – –
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early1950s [6].With the introductionof isoniazid,TB treatment
wasfirst considered feasible. Isoniazid inhibits the synthesis of
mycolic acids, an essential component of the bacterial cell
wall. At therapeutic levels isoniazid is bactericidal against
actively growing intracellular and extracellular MTB organ-
isms. Isoniazid is used in conjunction with other effective
anti-tuberculosis agents under multi-drug therapy [7].
Isoniazid is one of the most effective anti-TB drugs used
for TB treatment. This pro-drug requires activation, which is
carried out by the heme enzyme catalase/peroxidase (KatG)
of MTB. The mechanism of activation has not yet been clearly
understood as the binding interaction has not been appropri-
ately established [8]. Besides, InhA (2-trans-enoyl-acyl carrier
protein reductase) of MTB is a well-known target of INH [4]; a
few other targets have also been proposed in order to explain
the atypical potency of isoniazid [9].
Mechanisms of action of isoniazid
The mechanism of INH action has been the subject of rigor-
ous studies, but it is reported to generate a variety of highly
reactive compounds, including reactive oxygen species
(ROS) such as superoxide, peroxide and hydroxyl radicalFig. 2 – (A) Ramachandran plot of predicted KatG (S315T) mutan
mutant model. (C) Z plot of KatG (S315T). (D) Z plot of KatG (S31
determined by X-ray crystallography and NMR spectroscopy, wi
present in that range represented in the black dots.[10], and nitric oxide [11]; reactive organic species such as
isonicotinic acyl radical or anion [12]; and certain electrophilic
species [13], which then attack multiple targets in MTB [14].
INHpassively diffuses through themycobacterial envelope,
is activated byMnCl2 and the catalase–peroxidase KatG, possi-
bly into an isonicotinoyl radical or anion, which then inhibits
the InhA through a covalent attachment to NADH within the
active site of the protein. InhA has been shown to preferen-
tially catalyze the NADH-dependent reduction of 2-trans-
enoyl-ACP molecules with 16 or more carbons. This reaction
corresponds to the final step of elongation of the fatty acid.
In addition, INH inhibits the biosynthesis of mycolic acids,
which are extremely long chain fatty acids, specific to myco-
bacteria. A link between the inhibition of InhA and the inhibi-
tion of mycolic acid synthesis is provided by the fact that a
mutation in the inhA gene, which confers INH resistance, also
leads to the inhibition of mycolic acid biosynthesis to INH [4].
Study of the interaction of isoniazid with MTB enzymes
through a bioinformatics approach
INH resistance in TB is a complex process. Mutations in sev-
eral genes, including katG, inhA, ahpC, ndh and kasA, were
reported to associate with isoniazid resistance [15]. The rapidt model. (B) Ramachandran plot of predicted KatG (S315N)
5N) model. ProSA-web Z-scores of all protein chains in PDB,
th respect to their length. The Z-score of KatG mutants were
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information generated after the whole genome sequencing
of MTB will be useful in understanding the mechanism of
INH resistance.
Sandgren et al. compiled a comprehensive list of the
genetic polymorphisms associated with first- and second-line
drug resistance in clinical MTB isolates throughout the world
and reported that there were 22 genes of MTB which were
associated with INH resistance [16]. As per TB drug resistance
mutation database [16], 22 genes/proteins of MTB were
reported to associate with INH resistance (Table 1). Mutation
of amino acids in different enzymes is shown in Table 1.
Out of 22 proteins, 9 proteins have a known experimentally
determined 3D-structure available at the Protein Data Bank.
Two proteins-katG and InhA-are reported to interact with
INH. In this study, the interaction of INH with KatG and InhA
through molecular docking analysis was explored.
Materials and methods
Hardware and software
The study was carried out on a Dell Workstation with a
2.26 GHz processor, 6 GB RAM and 500 GB hard drive running
in aWindows operating system. Bioinformatics software, such
as AutoDock4.2 and online resources were used in this study.
M. tuberculosis KatG and InhA protein
Two important proteins ofMTB–KatG and InhA-are reported to
be directly involved in INH resistance, and the experimentally
determined structures of both the proteins obtained throughFig. 3 – (A) 3D structure of KatG; Docking interaction of INH with
KatG S315T mutant; and (D) KatG S315N mutant showing hydrothe X-ray diffraction experiment are available at the Protein
Data Bank (PDB) [17]. The three-dimensional structure of KatG
(PDB ID: 2CCA) and InhA (PDB ID: 1P44) were retrieved from the
PDB for docking study. Twomutants of KatG (S315Tand S315N)
were generated using Modeller9v10 [18].
Ligand preparation
The ligand (INH) used in this study against KatG was retrieved
from the PubChemdatabase [19]. INH-NADadductwas used as
another ligand against InhA, and PRODRG2 Server [20] was
used to obtain the chemical structure of INH-NAD adduct in
PDB format.
Protein–ligand docking
Protein–ligand docking studies were performed using the
AutoDock4.2 program [21]. It is one of the most widely used
methods for protein–ligand docking. All the pre-processing
steps for ligand and protein files were performed using the
AutoDock Tools 1.5.4 program (ADT) which has been released
as an extension suite to the PythonMolecular Viewer [21]. The
ADT program was used to prepare receptor molecules (KatG
and InhA) by adding all hydrogen atoms into the carbon
atoms of the receptor and Kollman charges were also
assigned. For docked ligands, non-polar hydrogens were also
added. Gasteiger charges were assigned and torsion degrees
of freedom were allocated by the ADT program.
The Lamarckian genetic algorithm (LGA) was applied to
model the interaction pattern between receptors and the
ligand. The grid maps representing the receptor proteins in(B) wild type KatG (no H-bond with Serine315) whereas (C)
gen bonds in dotted lines.
Fig. 4 – (A) Radical formation in the presence of Serine (wild
type strain) (Postulated pathway of NO production.
Oxidation of INH (1) at N2 to form the hydrazyl radical (2) is
followed by oxygen addition to the hydrazyl radical (causing
N–O bond formation) (3), followed by as yet undelineated
fragmentation or elimination [11]; (B) H-bond formation
(between –CO of Thr315 and –NH of INH) and prevention of a
radical formation in the presence of Threonine in place of
Serine (resistant strain).
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the AutoDock package). A grid of 40, 40 and 40 points in x, y,
and z directions was centered on the known active site resi-
dues of each protein. For all docking procedures, 10 indepen-
dent genetic algorithm (GA) runs with population size 150
were considered for each molecule under study. A maximum
number of 25 · 105 energy evaluations; 27,000 maximum gen-
erations; a gene mutation rate of 0.02 and a crossover rate of
0.8 were used for Lamarckian genetic algorithm. The Auto-
Dock program was run in order to prepare corresponding
DLGs (docking log files) for further analysis.
Visualization
The visualization of structure files was done using graphical
interface of ADT tool and PyMol molecular graphics system
(www.pymol.org).
Results and discussion
Validation of model
KatG of MTB encoded by Rv1908c has 740 amino acids in its
protein sequence whereas there are 269 amino acids in the
protein sequence of InhA (enoyl-[acyl carrier protein] reduc-
tase) encoded by Rv1484. Three-dimensional structures of
both the proteins are available at PDB. The single amino acid
mutation at codon 315, i.e., Ser to Thr (AGC–ACC) of the KatG
gene is reported to be the most widespread mutation, associ-
ated with INH resistance [22]. Another mutation, Ser315Asn
(AGC/AAC), was also reported in the INH resistance strain
[23]. Thus, mutant models of KatG (S315T and S315N) were
generated and subjected for validation. The stereochemistry
of the KatG (S315T) model (Procheck analysis) revealed that
92.8% of residues were situated in the most favorable region
and 7.2% were in additional allowed regions, whereas none
of the residues fell in the generously allowed and disallowed
region of the Ramachandran plot (Fig. 2A). In the case of the
KatG (S315N) model, 93.3% of residues were found in the most
favorable region and 6.7% in the additional allowed regions
(Fig. 2B). ProSA-web evaluation revealed a compatible Z score
value of 11.85 and 11.87 for the KatG (S315T) (Fig. 2C) and
the KatG (S315N) (Fig. 2D) models, respectively, which are well
within the range of the native conformations of crystal struc-
tures [24]. The overall residue energies of both the mutant
models were largely negative. The 3D model of both mutants
showed an LG score of around 4.8 by the Protein Quality Pre-
dictor (ProQ) tool, implying the high accuracy level of the pre-
dicted structure. A ProQ LG score >2.5 is necessary for
suggesting that a model is of very good quality [25].
Docking analysis of KatG and isoniazid
On the basis of the crystal structure of KatG (PDB ID: 2CCA)
(Fig. 3A), three-dimensional structures of two mutants were
obtained. The protein (KatGs) – ligand (INH) was performed
using AutoDock4.2 software [21]. Out of the ten poses
obtained, the best ligand pose was selected based on the
lowest binding energy confirmation. As the amino acid
(Serine) at 315 position of KatG was reported to haveundergone a mutation in most of the INH resistance strains,
docking of INH was performed around this amino acid posi-
tion. Upon docking, INH interacts with thewild type KatG pro-
tein with binding energy of 5.36 kcal/mol, whereas in case of
KatG (S315T) and KatG (S315N) mutants, the binding energies
were found to be 4.98 and 5.15 kcal/mol respectively. How-
ever, there was not much variation in the binding energy of
the protein–ligand complex in all three cases, but there was
no hydrogen bond formation observed between INH with
Ser315 residues of wild type KatG (Fig. 3B), while in the case
of the mutant strains – KatG (S315T) and KatG (S315N) – there
was a hydrogen-bond formation between INH with Thr315
(Fig. 3C) and Asn315 (Fig. 3D) with a bond length of 2.23 and
2.079 A˚, respectively.
Timmins et al. [11] demonstrated the generation of nitric
oxide upon the activation of INH by KatG (Fig. 4A) [11]. The
INH-derived NO had biological activity and was shown to be
involved in antimycobacterial action [11]. In this docking
study, it was also revealed that the Threonine residues of
the KatG (S315T) mutant (Fig. 4B) and the Asparagine residue
of the KatG (S315N) mutant formed one H-bond with -NH
atom of INH. As the hydrogen bond formation has shown to
Fig. 5 – Docking of InhA with (A) isoniazid (INH) (with binding energy of 4.75 kcal/mol) and (B) INH-NAD (with binding energy
of 6.25 kcal/mol).
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radical formation in the mutant strains that may lead to
INH resistance.
Docking analysis of InhA and INH/INH-NAD adduct
INH was reported to act on M. tuberculosis by inhibiting a 2-
trans-enoyl-acyl carrier protein reductase, called InhA
encoded by Rv1484 [4]. INH-NAD adduct was also reported as
a capable InhA inhibitor [27,28]. In this study, docking analysis
was performed between InhA with INH and INH-NAD adduct
separately. Tyr158 of InhA is reported as an important binding
site residue that interacts with the long chain fatty acyl sub-
strates, required for the synthesis of mycolic acids, a major
component of mycobacterial cell walls [29]. Docking of InhA
with isoniazid/INH-NAD adduct was performed around sub-
strate binding residue Tyr158. Isoniazid binds with InhA with
binding energy of 4.75 kcal/mol and the inhibition constant
of the protein–ligand complex (Fig. 5A) was found to be
328.38 lM, while INH-NAD adduct binds with InhA with the
lowest binding energy of 6.25 kcal/mol as compared with
INH only. INH-NAD adduct also formed one H-bond with a
known binding site residue Tyr158 (Fig. 5B). This docking anal-
ysis revealed that the INH-NAD adduct had more binding
affinity towards InhAwith the inhibition constant of 26.4 lM,
as compared with INH. This in silico docking study correlates
with an earlier in vitro study by Nguyen et al. reporting that
the INH-NAD adduct as a powerful inhibitor of InhA [27].
Conclusion
The computational approach has been employed to study the
interaction between INH with KatG and its mutant models.
The in silico docking study revealed that the mutation in KatG
at amino acid position 315 (S315T/S315N) might be involved in
hydrogen bond formation between INH with mutant Thr(T)/
Asn(N) residues. This H-bond formation may hamperINH-derived free radical formation. In wild type KatG, no H-
bond formation occurred between Ser315 residue and INH
that may lead to free radical formation which may be toxic
to mycobacterium. Furthermore, the interaction between
INH and INH-NAD adduct with InhA showed that the
INH-NAD adduct is more effectively inhibiting InhA. This
toxic consequence of INH with other MTB proteins needs to
be explored further in order to design novel drugs against
the pathogen.
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